SecBot SecBot
SECBOTREPLAY Home › Report › LGND

LGND · Ligand Pharmaceuticals announced FDA approval for FILSPARI (sparsentan)…

Ligand Pharmaceuticals · PRESS-RELEASE filed Apr 14, 2026 at 07:00 ET

At the news

BULLISHIMPACT 8/10

PRESS-RELEASE filed Apr 14, 2026 at 07:00 ET

Ligand Pharmaceuticals announced FDA approval for FILSPARI (sparsentan) to treat focal segmental glomerulosclerosis (FSGS), a rare kidney disorder, marking the first approved therapy for this condition. Ligand is entitled to a 9% royalty on worldwide net sales of FILSPARI, which expands its commercial potential beyond IgA nephropathy and positions it as a key driver of future royalty growth.

  • FDA approved FILSPARI for FSGS in patients aged 8+ without nephrotic syndrome, the first and only approved treatment for this indication.
  • Ligand receives a 9% royalty on worldwide net sales of FILSPARI, which is already the most prescribed FDA-approved drug for IgA nephropathy.
  • Phase 3 DUPLEX study showed a 46% reduction in proteinuria overall and 48% in non-nephrotic syndrome patients, with statistically significant results.
  • Addressable U.S. population estimated at over 30,000 patients with FSGS without nephrotic syndrome.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access